OPKO Health, Inc. (NASDAQ:OPK – Get Rating) CEO Phillip Md Et Al Frost acquired 50,000 shares of the stock in a transaction on Monday, September 26th. The stock was bought at an average price of $1.80 per share, with a total value of $90,000.00. Following the transaction, the chief executive officer now directly owns 197,756,694 shares in the company, valued at approximately $355,962,049.20. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.
Phillip Md Et Al Frost also recently made the following trade(s):
Get OPKO Health alerts:- On Friday, September 23rd, Phillip Md Et Al Frost purchased 50,000 shares of OPKO Health stock. The shares were acquired at an average price of $1.85 per share, with a total value of $92,500.00.
- On Wednesday, September 21st, Phillip Md Et Al Frost purchased 50,000 shares of OPKO Health stock. The shares were acquired at an average price of $1.91 per share, with a total value of $95,500.00.
- On Monday, September 19th, Phillip Md Et Al Frost purchased 50,000 shares of OPKO Health stock. The shares were acquired at an average price of $1.97 per share, with a total value of $98,500.00.
- On Thursday, September 15th, Phillip Md Et Al Frost purchased 200,000 shares of OPKO Health stock. The shares were acquired at an average price of $2.06 per share, with a total value of $412,000.00.
- On Wednesday, August 17th, Phillip Md Et Al Frost purchased 200,000 shares of OPKO Health stock. The shares were acquired at an average price of $2.54 per share, with a total value of $508,000.00.
- On Friday, August 5th, Phillip Md Et Al Frost acquired 350,000 shares of OPKO Health stock. The shares were purchased at an average price of $2.29 per share, with a total value of $801,500.00.
OPKO Health Stock Performance
Shares of OPK opened at $1.86 on Wednesday. The company has a debt-to-equity ratio of 0.12, a quick ratio of 1.91 and a current ratio of 2.30. OPKO Health, Inc. has a twelve month low of $1.78 and a twelve month high of $5.25. The firm's 50 day moving average price is $2.30 and its two-hundred day moving average price is $2.75. The firm has a market cap of $1.44 billion, a P/E ratio of -6.41 and a beta of 1.75.
OPKO Health (NASDAQ:OPK – Get Rating) last announced its quarterly earnings results on Thursday, August 4th. The biotechnology company reported ($0.04) earnings per share for the quarter, missing analysts' consensus estimates of ($0.02) by ($0.02). OPKO Health had a negative net margin of 14.18% and a negative return on equity of 7.72%. The company had revenue of $309.90 million during the quarter, compared to the consensus estimate of $326.87 million. During the same period in the previous year, the firm posted ($0.03) EPS. The business's quarterly revenue was down 30.0% compared to the same quarter last year. On average, analysts forecast that OPKO Health, Inc. will post -0.38 EPS for the current fiscal year.Analyst Ratings Changes
Separately, Piper Sandler decreased their price objective on shares of OPKO Health from $5.00 to $4.00 and set an "overweight" rating for the company in a report on Friday, August 5th.
Institutional Trading of OPKO Health
Institutional investors have recently made changes to their positions in the business. Cornerstone Advisory LLC bought a new stake in shares of OPKO Health in the fourth quarter worth $29,000. Humankind Investments LLC bought a new stake in shares of OPKO Health in the first quarter worth $37,000. Guggenheim Capital LLC bought a new stake in shares of OPKO Health in the first quarter worth $38,000. Point72 Hong Kong Ltd bought a new stake in shares of OPKO Health in the first quarter worth $39,000. Finally, Aigen Investment Management LP bought a new stake in shares of OPKO Health in the second quarter worth $29,000. Institutional investors own 27.83% of the company's stock.
About OPKO Health
(Get Rating)
OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers and governmental units; and a novel diagnostic instrument system to provide blood test results in the point-of-care setting, as well as 4Kscore prostate cancer testing services.
Featured Articles
- Get a free copy of the StockNews.com research report on OPKO Health (OPK)
- Defensive Stocks For A Volatile Market
- Will UPS Be Next to Deliver a Warning?
- SunPower Is Ready To Power Up Triple-Digit Earnings Gains
- Is This the Darkest Before the Dawn for Gap Stock?
- Build A Better Tech Portfolio With Jabil Inc.
Receive News & Ratings for OPKO Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OPKO Health and related companies with MarketBeat.com's FREE daily email newsletter.